Abstract
In recent years, the incorporation of new cytostatic drugs to treat colorectal cancer (CRC) and adjuvant objective is to treat the disease or disseminated contributed to decrease the reoccurrence and increased overall patient survive and thus the advent of various toxicity profiles according to the scheme used. To describe the clinical and para clinical toxicity of one of the schemes more chemotherapy used for the treatment of RCC at the National Cancer Institute (INCA). METHODOLOGY: Longitudinal prospective study. An analysis was made after consideration of the direction of INCA medical records of 27 patients with CRC assisted at the service of such chemotherapy Institution in the June / 2008 - Dec / 2009. He had the free and informed consent of the patients to participate in the study, disguising personal data to protect your privacy. They are proceeded to complete the notebook data collection in order to determine the toxicity of CAPOX plan. Results: 27 patients, 11 females and 16 males were included with a 58 median age. In terms of tumor topography, 10 were right colon level 10 to level the left colon and 7 rectum level. 55.5% were stage III, stage IV 29.6% and 14.8% stage II. The
More>>
Aghazarian, M;
Larranaga, J;
Reyes, G;
Heinzen, S;
Ferrero, L;
Lasalvia, E;
Echague, P;
Estevez, F;
Citrin, E;
Viola, A.
[1]
- Instituto Nacional del Cancer, Ministerio de Salud Publica. Montevideo (Uruguay)
Citation Formats
Aghazarian, M, Larranaga, J, Reyes, G, Heinzen, S, Ferrero, L, Lasalvia, E, Echague, P, Estevez, F, Citrin, E, and Viola, A.
Prospective descriptive study of the toxicity of CAPOX plan in systemic treatment of colorectal cancer; Estudio descriptivo prospectivo de la toxicidad del plan CAPOX en el tratamiento sistemico del cancer colorrectal.
Uruguay: N. p.,
2010.
Web.
Aghazarian, M, Larranaga, J, Reyes, G, Heinzen, S, Ferrero, L, Lasalvia, E, Echague, P, Estevez, F, Citrin, E, & Viola, A.
Prospective descriptive study of the toxicity of CAPOX plan in systemic treatment of colorectal cancer; Estudio descriptivo prospectivo de la toxicidad del plan CAPOX en el tratamiento sistemico del cancer colorrectal.
Uruguay.
Aghazarian, M, Larranaga, J, Reyes, G, Heinzen, S, Ferrero, L, Lasalvia, E, Echague, P, Estevez, F, Citrin, E, and Viola, A.
2010.
"Prospective descriptive study of the toxicity of CAPOX plan in systemic treatment of colorectal cancer; Estudio descriptivo prospectivo de la toxicidad del plan CAPOX en el tratamiento sistemico del cancer colorrectal."
Uruguay.
@misc{etde_22454682,
title = {Prospective descriptive study of the toxicity of CAPOX plan in systemic treatment of colorectal cancer; Estudio descriptivo prospectivo de la toxicidad del plan CAPOX en el tratamiento sistemico del cancer colorrectal}
author = {Aghazarian, M, Larranaga, J, Reyes, G, Heinzen, S, Ferrero, L, Lasalvia, E, Echague, P, Estevez, F, Citrin, E, and Viola, A.}
abstractNote = {In recent years, the incorporation of new cytostatic drugs to treat colorectal cancer (CRC) and adjuvant objective is to treat the disease or disseminated contributed to decrease the reoccurrence and increased overall patient survive and thus the advent of various toxicity profiles according to the scheme used. To describe the clinical and para clinical toxicity of one of the schemes more chemotherapy used for the treatment of RCC at the National Cancer Institute (INCA). METHODOLOGY: Longitudinal prospective study. An analysis was made after consideration of the direction of INCA medical records of 27 patients with CRC assisted at the service of such chemotherapy Institution in the June / 2008 - Dec / 2009. He had the free and informed consent of the patients to participate in the study, disguising personal data to protect your privacy. They are proceeded to complete the notebook data collection in order to determine the toxicity of CAPOX plan. Results: 27 patients, 11 females and 16 males were included with a 58 median age. In terms of tumor topography, 10 were right colon level 10 to level the left colon and 7 rectum level. 55.5% were stage III, stage IV 29.6% and 14.8% stage II. The 27 patients included CAPOX plan received the standard dose with a median cycles of 7. The clinical toxicities more frequent were: sensory neuropathy (66.6%), diarrhea (48.1%), hand-foot syndrome (44.4%), nausea (37%), Vomiting (29.6%), mucositis (11.1%) observed less frequently: conjunctival irritation, hyperpigmentation skin, pharynx larynx dysesthesia, alopecia, and fatigue stress angina. Concerning the haematological toxicity It emphasizes that all patients had a decrease in platelet count during treatment with 44.4% of grade 1 thrombocytopenia, was 62.9% of anemia, leucopenia and 33.3% to 37.0% of neutropenia. Single one patient had mild elevation of serum creatinine. Liver enzyme toxicity occurred in 37% TGO level - GGT, 29.6% in the TGP; 29.6% in the FA and 66.6% of patients increased the number of LDH. Two patients had hyperbilirubinaemia, one grade 2 and one grade 3 to predominance of bilirubin indirect. Five patients had to discontinue treatment due to toxicity of the plan: 2 gastrointestinal (diarrhea G3), 2 and liver function (elevated bilirubin level 2 and 3) 1 cardiovascular (CF II effort angina). Of these 5 cases, in 4 patients the dose was reduced in the first instance and then rotate to another chemotherapy regimen and only patient who presented effort angina permanently stopped treatment. Conclusions: This is the first prospective descriptive work in the INCA to describe the toxicity of treatment a prevalent disease such as CCR. The most frequent toxicities observed in our study similar to those described in the international literature. Most adverse events occurred were mild to moderate (grade 1 and 2) where the toxicities grade 3 and more frequent gastrointestinal and hepatic level 4. The number Low of patients included could be due to the recent introduction of new drugs in the treatment of Metastatic RCC not included in this study as well as the non-inclusion of capecitabine also mono drug often used in metastatic CRC in elderly patients.}
place = {Uruguay}
year = {2010}
month = {Nov}
}
title = {Prospective descriptive study of the toxicity of CAPOX plan in systemic treatment of colorectal cancer; Estudio descriptivo prospectivo de la toxicidad del plan CAPOX en el tratamiento sistemico del cancer colorrectal}
author = {Aghazarian, M, Larranaga, J, Reyes, G, Heinzen, S, Ferrero, L, Lasalvia, E, Echague, P, Estevez, F, Citrin, E, and Viola, A.}
abstractNote = {In recent years, the incorporation of new cytostatic drugs to treat colorectal cancer (CRC) and adjuvant objective is to treat the disease or disseminated contributed to decrease the reoccurrence and increased overall patient survive and thus the advent of various toxicity profiles according to the scheme used. To describe the clinical and para clinical toxicity of one of the schemes more chemotherapy used for the treatment of RCC at the National Cancer Institute (INCA). METHODOLOGY: Longitudinal prospective study. An analysis was made after consideration of the direction of INCA medical records of 27 patients with CRC assisted at the service of such chemotherapy Institution in the June / 2008 - Dec / 2009. He had the free and informed consent of the patients to participate in the study, disguising personal data to protect your privacy. They are proceeded to complete the notebook data collection in order to determine the toxicity of CAPOX plan. Results: 27 patients, 11 females and 16 males were included with a 58 median age. In terms of tumor topography, 10 were right colon level 10 to level the left colon and 7 rectum level. 55.5% were stage III, stage IV 29.6% and 14.8% stage II. The 27 patients included CAPOX plan received the standard dose with a median cycles of 7. The clinical toxicities more frequent were: sensory neuropathy (66.6%), diarrhea (48.1%), hand-foot syndrome (44.4%), nausea (37%), Vomiting (29.6%), mucositis (11.1%) observed less frequently: conjunctival irritation, hyperpigmentation skin, pharynx larynx dysesthesia, alopecia, and fatigue stress angina. Concerning the haematological toxicity It emphasizes that all patients had a decrease in platelet count during treatment with 44.4% of grade 1 thrombocytopenia, was 62.9% of anemia, leucopenia and 33.3% to 37.0% of neutropenia. Single one patient had mild elevation of serum creatinine. Liver enzyme toxicity occurred in 37% TGO level - GGT, 29.6% in the TGP; 29.6% in the FA and 66.6% of patients increased the number of LDH. Two patients had hyperbilirubinaemia, one grade 2 and one grade 3 to predominance of bilirubin indirect. Five patients had to discontinue treatment due to toxicity of the plan: 2 gastrointestinal (diarrhea G3), 2 and liver function (elevated bilirubin level 2 and 3) 1 cardiovascular (CF II effort angina). Of these 5 cases, in 4 patients the dose was reduced in the first instance and then rotate to another chemotherapy regimen and only patient who presented effort angina permanently stopped treatment. Conclusions: This is the first prospective descriptive work in the INCA to describe the toxicity of treatment a prevalent disease such as CCR. The most frequent toxicities observed in our study similar to those described in the international literature. Most adverse events occurred were mild to moderate (grade 1 and 2) where the toxicities grade 3 and more frequent gastrointestinal and hepatic level 4. The number Low of patients included could be due to the recent introduction of new drugs in the treatment of Metastatic RCC not included in this study as well as the non-inclusion of capecitabine also mono drug often used in metastatic CRC in elderly patients.}
place = {Uruguay}
year = {2010}
month = {Nov}
}